Drugs and Devices

FDA approves Gazyva for chronic lymphocytic leukemia

On Nov. 1, the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares